Cabaletta Bio is trading down 5.29% now at $1.97, amid broad weakness in clinical-stage biotech stocks. - The XBI is down 2.50%; major U.S. indexes are higher, so the broader-market rally does not explain the decline. - No clear company-specific catalyst surfaced for the October 6 move. - On October 5, Cabaletta Bio disclosed inducement equity awards for four new employees; available information does not establish the announcement as the cause of the drop.